Nuwellis (NASDAQ:NUWE) Upgraded to “Hold” at Wall Street Zen

Nuwellis (NASDAQ:NUWE) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Nuwellis in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Nuwellis Trading Down 3.1%

NASDAQ:NUWE opened at $2.85 on Friday. Nuwellis has a 1 year low of $2.73 and a 1 year high of $577.50. The stock has a market cap of $228,000.00, a price-to-earnings ratio of -0.00 and a beta of 0.29. The stock has a 50-day moving average price of $14.05 and a two-hundred day moving average price of $43.53.

Nuwellis (NASDAQ:NUWE) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($73.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($35.00) by ($38.15). Nuwellis had a negative return on equity of 32,351.83% and a negative net margin of 214.90%.The business had revenue of $2.40 million during the quarter, compared to the consensus estimate of $2.09 million.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Nuwellis stock. Sabby Management LLC grew its holdings in shares of Nuwellis, Inc. (NASDAQ:NUWE) by 149.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 89,685 shares of the company’s stock after buying an additional 53,791 shares during the quarter. Nuwellis makes up 0.2% of Sabby Management LLC’s portfolio, making the stock its 18th largest position. Sabby Management LLC owned about 4.80% of Nuwellis worth $156,000 as of its most recent SEC filing. 3.13% of the stock is currently owned by institutional investors and hedge funds.

Nuwellis Company Profile

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.